Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
DOI: | 10.29021/spdv.79.1.1277 |
Texto Completo: | https://doi.org/10.29021/spdv.79.1.1277 |
Resumo: | Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies. |
id |
RCAP_03f516a3228ab99aa6589a9fc8b35df7 |
---|---|
oai_identifier_str |
oai:ojs.revista.spdv.com.pt:article/1277 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical CasesTratamento do Linfoma Cutâneo Primário de Células Grandes Anaplásicas com Brentuximab Vedotina: A Propósito de Dois Casos ClínicosBrentuximab VedotinLymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapyLymphoma, T-CellCutaneous/drug therapySkin Neoplasms/drug therapyBrentuximab VedotinaLinfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológicoLinfoma Cutâneo de Células T/tratamento farmacológicoNeoplasias da Pele/tratamento farmacológicoBrentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.O brentuximab vedotina está aprovado pela Food and Drug Administration (FDA) e pela European Medicines Agency (EMA) para o tratamento de doentes adultos com linfomas cutâneos primários de células T CD30+, refratários a pelo menos uma linha terapêutica prévia. Os autores reportam dois casos clínicos de linfoma cutâneo primário de células grandes anaplásicas, tratados com brentuximab vedotina, com respostas clínicas distintas. Não obstante, o brentuximab vedotina poderá constituir uma alternativa terapêutica válida para o tratamento destas patologias.Sociedade Portuguesa de Dermatologia e Venereologia2021-04-05T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.29021/spdv.79.1.1277oai:ojs.revista.spdv.com.pt:article/1277Journal of the Portuguese Society of Dermatology and Venereology; Vol 79 No 1 (2021): January - March; 53-56Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 79 n. 1 (2021): Janeiro - Março; 53-562182-24092182-2395reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spdv.com.pt/index.php/spdv/article/view/1277https://doi.org/10.29021/spdv.79.1.1277https://revista.spdv.com.pt/index.php/spdv/article/view/1277/886Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereologyhttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessFerreira, SandraFernandes, IolandaCabral, RenataLima, Margarida2022-10-06T12:35:17Zoai:ojs.revista.spdv.com.pt:article/1277Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:11:18.233620Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases Tratamento do Linfoma Cutâneo Primário de Células Grandes Anaplásicas com Brentuximab Vedotina: A Propósito de Dois Casos Clínicos |
title |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
spellingShingle |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases Ferreira, Sandra Brentuximab Vedotin Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy Lymphoma, T-Cell Cutaneous/drug therapy Skin Neoplasms/drug therapy Brentuximab Vedotina Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico Linfoma Cutâneo de Células T/tratamento farmacológico Neoplasias da Pele/tratamento farmacológico Ferreira, Sandra Brentuximab Vedotin Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy Lymphoma, T-Cell Cutaneous/drug therapy Skin Neoplasms/drug therapy Brentuximab Vedotina Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico Linfoma Cutâneo de Células T/tratamento farmacológico Neoplasias da Pele/tratamento farmacológico |
title_short |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
title_full |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
title_fullStr |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
title_full_unstemmed |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
title_sort |
Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases |
author |
Ferreira, Sandra |
author_facet |
Ferreira, Sandra Ferreira, Sandra Fernandes, Iolanda Cabral, Renata Lima, Margarida Fernandes, Iolanda Cabral, Renata Lima, Margarida |
author_role |
author |
author2 |
Fernandes, Iolanda Cabral, Renata Lima, Margarida |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Ferreira, Sandra Fernandes, Iolanda Cabral, Renata Lima, Margarida |
dc.subject.por.fl_str_mv |
Brentuximab Vedotin Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy Lymphoma, T-Cell Cutaneous/drug therapy Skin Neoplasms/drug therapy Brentuximab Vedotina Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico Linfoma Cutâneo de Células T/tratamento farmacológico Neoplasias da Pele/tratamento farmacológico |
topic |
Brentuximab Vedotin Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy Lymphoma, T-Cell Cutaneous/drug therapy Skin Neoplasms/drug therapy Brentuximab Vedotina Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico Linfoma Cutâneo de Células T/tratamento farmacológico Neoplasias da Pele/tratamento farmacológico |
description |
Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-04-05T00:00:00Z |
dc.type.driver.fl_str_mv |
journal article info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.29021/spdv.79.1.1277 oai:ojs.revista.spdv.com.pt:article/1277 |
url |
https://doi.org/10.29021/spdv.79.1.1277 |
identifier_str_mv |
oai:ojs.revista.spdv.com.pt:article/1277 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revista.spdv.com.pt/index.php/spdv/article/view/1277 https://doi.org/10.29021/spdv.79.1.1277 https://revista.spdv.com.pt/index.php/spdv/article/view/1277/886 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology https://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology https://creativecommons.org/licenses/by-nc/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
dc.source.none.fl_str_mv |
Journal of the Portuguese Society of Dermatology and Venereology; Vol 79 No 1 (2021): January - March; 53-56 Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 79 n. 1 (2021): Janeiro - Março; 53-56 2182-2409 2182-2395 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1822218921339518976 |
dc.identifier.doi.none.fl_str_mv |
10.29021/spdv.79.1.1277 |